Skip header and navigation

Refine By

925 records – page 1 of 93.

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.

https://arctichealth.org/en/permalink/ahliterature176202
Source
Contraception. 2005 Feb;71(2):111-7
Publication Type
Article
Date
Feb-2005
Author
Sven O Skouby
Jan Endrikat
Bernd Düsterberg
Werner Schmidt
Christoph Gerlinger
Jens Wessel
Henri Goldstein
Joergen Jespersen
Author Affiliation
Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark. sven.skouby@fh.hosp.dk
Source
Contraception. 2005 Feb;71(2):111-7
Date
Feb-2005
Language
English
Publication Type
Article
Keywords
Adult
Blood Glucose - metabolism
C-Peptide - blood
Carbohydrate Metabolism - drug effects
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Contraceptive Agents, Female - administration & dosage - pharmacology
Contraceptives, Oral, Combined - administration & dosage - pharmacology
Denmark
Dose-Response Relationship, Drug
Ethinyl Estradiol - administration & dosage - pharmacology
Fatty Acids, Nonesterified - blood
Female
Humans
Insulin - blood
Levonorgestrel - administration & dosage - pharmacology
Lipid Metabolism - drug effects
Prospective Studies
Time Factors
Treatment Outcome
Triglycerides - blood
Abstract
To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives.
In an open-label, randomized study, a dose-reduced oral contraceptive containing 20 microg EE and 100 microg LNG (20 EE/100 LNG) was compared with a reference preparation containing 30 microg EE and 150 microg LNG (30 EE/150 LNG). One-year data from 48 volunteers were obtained.
We found a decrease of HDL2 cholesterol and increases of low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol and total triglycerides in both treatment groups from baseline to the 13th treatment cycle. Although for four of six variables, the changes in the 20 EE group were lower compared with the 30 EE group, none of the differences between the two treatments were statistically significant. The median values for the fasting levels of insulin, C-peptide and free fatty acids slightly increased or remained unchanged while the fasting glucose levels slightly decreased after 13 treatment cycles. While the glucose area under the curve (AUC) (0-3 h) was similar in both groups during the OGTT, the insulin AUC(0-3 h) was less increased in the 20 EE/100 LNG group compared with the 30 EE/150 LNG group. None of the differences between the treatment groups for any of the carbohydrate metabolism variables were statistically significant at any time point. Both study treatments were safe and well tolerated by the volunteers.
Similar effects on the lipid and carbohydrate profiles were found for both preparations. The balanced one-third EE dose reduction in this new oral contraceptive caused slightly lower, but insignificant, changes in the lipid and carbohydrate variables compared with the reference treatment.
PubMed ID
15707560 View in PubMed
Less detail

2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus.

https://arctichealth.org/en/permalink/ahliterature121853
Source
Cardiovasc Diabetol. 2012;11:93
Publication Type
Article
Date
2012
Author
Loghman Henareh
Stefan Agewall
Author Affiliation
Department of Cardiology Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. loghman.henareh@karolinska.se
Source
Cardiovasc Diabetol. 2012;11:93
Date
2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Angina, Unstable - blood - epidemiology - mortality
Biological Markers - blood
Blood Glucose - metabolism
Chi-Square Distribution
Female
Glucose Tolerance Test
Humans
Incidence
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction - blood - epidemiology - mortality
Predictive value of tests
Prognosis
Proportional Hazards Models
Prospective Studies
Recurrence
Risk assessment
Risk factors
Smoking - adverse effects - epidemiology
Stroke - blood - epidemiology - mortality
Sweden - epidemiology
Time Factors
Abstract
The incidence of cardiovascular events remains high in patients with myocardial infarction (MI) despite advances in current therapies. New and better methods for identifying patients at high risk of recurrent cardiovascular (CV) events are needed. This study aimed to analyze the predictive value of an oral glucose tolerance test (OGTT) in patients with acute myocardial infarction without known diabetes mellitus (DM).
The prospective cohort study consisted of 123 men and women aged between 31-80 years who had suffered a previous MI 3-12 months before the examinations. The exclusion criteria were known diabetes mellitus. Patients were followed up over 6.03???1.36 years for CV death, recurrent MI, stroke and unstable angina pectoris. A standard OGTT was performed at baseline.
2-h plasma glucose (HR, 1.27, 95% CI, 1.00 to 1.62; P?
Notes
Cites: N Engl J Med. 2000 Jan 20;342(3):145-5310639539
Cites: Cardiovasc Diabetol. 2012;11:2122397368
Cites: Am J Med. 2000 Nov;109(7):538-4211063954
Cites: J Clin Invest. 2001 Aug;108(4):635-611518739
Cites: Diabetologia. 2001 Sep;44 Suppl 2:S54-6411587051
Cites: Circulation. 2001 Nov 27;104(22):2673-811723017
Cites: Diabetes Care. 2001 Dec;24(12):2043-811723080
Cites: BMJ. 2002 Jan 12;324(7329):71-8611786451
Cites: Dtsch Med Wochenschr. 2002 May 3;127(18):953-711987015
Cites: Eur Heart J. 2002 Aug;23(16):1267-7512175663
Cites: Diabetes Care. 2002 Oct;25(10):1845-5012351489
Cites: Int J Cardiol. 2004 Oct;97(1):21-415336801
Cites: Eur Heart J. 1985 Mar;6(3):199-2262863148
Cites: J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-672698218
Cites: Am J Hypertens. 1994 Jul;7(7 Pt 1):615-227946163
Cites: Lancet. 1994 Nov 19;344(8934):1383-97968073
Cites: BMJ. 1995 Mar 4;310(6979):555-97888928
Cites: Diabetes Care. 1996 Mar;19(3):257-678742574
Cites: Diabetologia. 1996 Dec;39(12):1577-838960845
Cites: Diabetes Care. 1998 Sep;21(9):1529-339727904
Cites: Circ Res. 1999 Mar 19;84(5):489-9710082470
Cites: Diabetes Care. 1999 Jun;22(6):920-410372242
Cites: J Am Coll Cardiol. 1999 Jul;34(1):146-5410400004
Cites: Lancet. 1999 Aug 21;354(9179):617-2110466661
Cites: Eur Heart J. 2004 Nov;25(22):1990-715541834
Cites: Am J Cardiol. 2005 Aug 1;96(3):363-516054458
Cites: Diabet Med. 2005 Sep;22(9):1212-716108851
Cites: Clin Ther. 2005;27 Suppl B:S42-5616519037
Cites: Clin Physiol Funct Imaging. 2007 Jan;27(1):60-617204040
Cites: Circ J. 2007 Jun;71(6):834-4117526977
Cites: Circulation. 2007 Jul 10;116(2):151-717576864
Cites: Circulation. 2007 Nov 27;116(22):2634-5317951284
Cites: Heart Vessels. 2009 Mar;24(2):90-519337791
Cites: Prim Care Diabetes. 2009 Nov;3(4):205-919875348
Cites: Diabetes Care. 2010 Jan;33 Suppl 1:S62-920042775
Cites: Cardiovasc Diabetol. 2010;9:7521070650
Cites: Cardiovasc Diabetol. 2011;10:5621702911
Cites: Hypertension. 2000 Aug;36(2):245-910948085
PubMed ID
22873202 View in PubMed
Less detail

A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood.

https://arctichealth.org/en/permalink/ahliterature32420
Source
J Diabetes Complications. 2000 Nov-Dec;14(6):295-300
Publication Type
Article
Author
B S Olsen
A. Sjølie
P. Hougaard
J. Johannesen
K. Borch-Johnsen
K. Marinelli
B. Thorsteinsson
S. Pramming
H B Mortensen
Author Affiliation
Department of Paediatrics, Glostrup University Hospital, DK-2600, Glostrup, Denmark.
Source
J Diabetes Complications. 2000 Nov-Dec;14(6):295-300
Language
English
Publication Type
Article
Keywords
Adolescent
Albuminuria - epidemiology
Blood Glucose - metabolism
Child
Cohort Studies
Denmark - epidemiology
Diabetes Mellitus, Type 1 - blood - drug therapy - physiopathology
Diabetic Nephropathies - epidemiology - prevention & control
Diabetic Neuropathies - epidemiology - prevention & control
Diabetic Retinopathy - epidemiology - prevention & control
Female
Humans
Male
Neurologic Examination
Perception
Probability
Risk factors
Vibration
Abstract
The study aimed to identify risk markers (present at the start of the study in 1989) for the occurrence and progression of microvascular complications 6 years later (in 1995) in a Danish nationwide cohort of children and adolescents with Type 1 diabetes (average age at entry 13.7 years). Probabilities for the development of elevated albumin excretion rate (AER), retinopathy, and increased vibration perception threshold (VPT) could then be estimated from a stepwise logistic regression model. A total of 339 patients (47% of the original cohort) were studied. Sex, age, diabetes duration, insulin regimen and dose, height, weight, HbA(1c), blood pressure, and AER were recorded. In addition, information on retinopathy, neuropathy (VPT), and anti-hypertensive treatment was obtained at the end of the study. HbA(1c) (normal range 4.3-5.8, mean 5.3%) and AER (upper normal limit or =20 microg min(-1)) was found in 12.8% of the patients in 1995, and risk markers for this were increased AER and high HbA(1c), in 1989 (both p6.5 V) was found in 62.5% of patients in 1995, for which the risk markers were male sex (p
PubMed ID
11120452 View in PubMed
Less detail

7(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG), May 8-10, 2014, Helsinki, Finland.

https://arctichealth.org/en/permalink/ahliterature264876
Source
Diabetes Technol Ther. 2014 Nov;16(11):794-815
Publication Type
Conference/Meeting Material
Article
Date
Nov-2014
Author
Christopher G Parkin
Anita Mlinac
Rolf Hinzmann
Source
Diabetes Technol Ther. 2014 Nov;16(11):794-815
Date
Nov-2014
Language
English
Publication Type
Conference/Meeting Material
Article
Keywords
Blood Glucose - metabolism
Blood Glucose Self-Monitoring - trends
Diabetes Mellitus - blood
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 2 - blood
Finland
Guidelines as Topic
Humans
Hypoglycemic Agents - administration & dosage
Insulin - administration & dosage
Monitoring, Ambulatory
Patient compliance
Abstract
International experts in the fields of diabetes, diabetes technology, endocrinology, mobile health, sport science, and regulatory issues gathered for the 7(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG). The aim of this meeting was to facilitate new collaborations and research projects to improve the lives of people with diabetes. The 2014 meeting comprised a comprehensive scientific program, parallel interactive workshops, and two keynote lectures.
Notes
Cites: Diabet Med. 2011 Oct;28(10):1158-6721294770
Cites: Diabetes Care. 2012 Feb;35(2):204-1022210571
Cites: Diabetes Res Clin Pract. 2012 Oct;98(1):5-1022917639
Cites: J Diabetes Sci Technol. 2012 Sep;6(5):1060-7523063032
Cites: Pediatr Diabetes. 2012 Nov;13(7):545-5122776045
Cites: Diabetologia. 2013 Feb;56(2):284-9323093136
Cites: Diabetes Technol Ther. 2013 Feb;15(2):166-7123259764
Cites: J Diabetes Sci Technol. 2013;7(1):144-5223439170
Cites: J Diabetes Sci Technol. 2013;7(1):156-6223439172
Cites: N Engl J Med. 2013 Jul 18;369(3):224-3223789889
Cites: Pediatr Diabetes. 2013 Sep;14(6):422-822957743
Cites: Diabetes Care. 2013 Oct;36(10):2887-9423735724
Cites: Diabetes Care. 2013 Nov;36(11):3535-4223900589
Cites: BMC Pediatr. 2013;13:16324106787
Cites: Diabetes Metab. 2000 Apr;26(2):118-2410804326
Cites: N Engl J Med. 2001 May 3;344(18):1343-5011333990
Cites: Diabetes Care. 2001 Oct;24(10):1722-711574432
Cites: Mol Cell Endocrinol. 2001 Dec 20;185(1-2):93-811738798
Cites: Diabetologia. 2002 Mar;45(3):342-811914739
Cites: Diabet Med. 2002 Apr;19(4):265-7311942996
Cites: Diabetes. 2002 Jul;51(7):2321-412086968
Cites: Diabetes Care. 2003 Sep;26(9):2598-60312941725
Cites: J Consult Clin Psychol. 2004 Feb;72(1):31-4014756612
Cites: Prev Med. 2004 Jul;39(1):164-715207998
Cites: Lancet. 1989 Sep 9;2(8663):577-802570282
Cites: BMJ. 1991 Oct 26;303(6809):1019-221954451
Cites: Diabetes. 2011 May;60(5):1528-3421471513
Cites: Lancet. 2011 Jul 2;378(9785):49-5521722952
Cites: BMJ. 2011;343:d380521737469
Cites: Diabetes Care. 2011 Sep;34(9):1934-4221788632
Cites: Diabetes Care. 2011 Sep;34(9):2023-521868778
Cites: Int J Pharm Pract. 2011 Oct;19(5):342-921899614
Cites: PLoS One. 2011;6(8):e2407021904606
Cites: Diabetes Care. 2013 Dec;36(12):4160-224103902
Cites: Diabetes Care. 2013 Dec;36(12):4063-7024130355
Cites: J Diabetes Sci Technol. 2013 Nov;7(6):1585-9424351185
Cites: Clin Pharmacol Ther. 2014 Feb;95(2):147-5324060819
Cites: BMC Pregnancy Childbirth. 2014;14:7024524674
Cites: Acta Diabetol. 2014 Apr;51(2):205-1023681558
Cites: Diabetologia. 2014 Aug;57(8):1578-8524893863
Cites: Diabetes Care. 2011 Feb;34(2):262-721270183
Cites: Diabetes Care. 2011 Mar;34(3):574-921278138
Cites: Diabetes Care. 2014 Aug;37(8):2114-2224854041
Cites: Diabetes Res Clin Pract. 2013 Jul;101(1):57-6123726303
Cites: BMJ. 1994 May 21;308(6940):1323-88019217
Cites: Arch Dis Child. 1998 Feb;78(2):111-59579150
Cites: BMJ. 1999 Feb 13;318(7181):427-319974455
Cites: BMJ. 2006 Jul 8;333(7558):6516803942
Cites: Diabetes Care. 2006 Dec;29(12):2644-917130198
Cites: Diabetes Metab. 2007 Apr;33(2):158-6617300973
Cites: Pediatr Diabetes. 2008 Aug;9(4 Pt 2):360-618774996
Cites: N Engl J Med. 2008 Oct 2;359(14):1464-7618779236
Cites: Diabet Med. 2008 Sep;25(9):1036-4218937673
Cites: Ann Med. 2009;41(1):66-7218720095
Cites: Evid Rep Technol Assess (Full Rep). 2008 Nov;(175):1-142219408968
Cites: Pediatr Diabetes. 2009 Aug;10(5):298-30319175902
Cites: Diabetes Care. 2009 Dec;32(12):2245-5019767384
Cites: Diabetes Care. 2010 Jan;33(1):23-819837786
Cites: Diabetes Technol Ther. 2010 Mar;12(3):221-3120151773
Cites: Pediatr Diabetes. 2010 Feb;11(1):24-720015124
Cites: Pediatr Diabetes. 2010 Mar;11(2):116-2119566740
Cites: J Psychosom Res. 2010 Jun;68(6):539-4420488270
Cites: J Diabetes Sci Technol. 2010 May;4(3):562-7020513321
Cites: Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):380-9520633742
Cites: N Engl J Med. 2010 Jul 22;363(4):311-2020587585
Cites: Diabetes Care. 2011 Jan;34(1):50-220929999
PubMed ID
25211215 View in PubMed
Less detail

A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.

https://arctichealth.org/en/permalink/ahliterature149324
Source
Diabetes. 2009 Nov;58(11):2649-55
Publication Type
Article
Date
Nov-2009
Author
Johan Wadén
Carol Forsblom
Lena M Thorn
Daniel Gordin
Markku Saraheimo
Per-Henrik Groop
Author Affiliation
Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. per-henrik.groop@helsinki.fi
Source
Diabetes. 2009 Nov;58(11):2649-55
Date
Nov-2009
Language
English
Publication Type
Article
Keywords
Adult
Albuminuria - epidemiology
Autoanalysis - methods
Biological Markers - blood
Blood pressure
Cardiovascular Diseases - epidemiology - mortality
Diabetes Mellitus, Type 1 - blood
Diabetic Angiopathies - epidemiology - mortality
Diabetic Nephropathies - epidemiology - mortality
Female
Finland - epidemiology
Follow-Up Studies
Glucose - metabolism
Hemoglobin A, Glycosylated - metabolism
Humans
Kidney Failure, Chronic - epidemiology
Lipids - blood
Male
Middle Aged
Patient Selection
Predictive value of tests
Risk factors
Survival Rate
Abstract
Recent data from the Diabetes Control and Complications Trial (DCCT) indicated that A1C variability is associated with the risk of diabetes microvascular complications. However, these results might have been influenced by the interventional study design. Therefore, we investigated the longitudinal associations between A1C variability and diabetes complications in patients with type 1 diabetes in the observational Finnish Diabetic Nephropathy (FinnDiane) Study.
A total of 2,107 patients in the FinnDiane Study had complete data on renal status and serial measurements of A1C from baseline to follow-up (median 5.7 years), and 1,845 patients had similar data on cardiovascular disease (CVD) events. Intrapersonal SD of serially measured A1C was considered a measure of variability.
During follow-up, 10.2% progressed to a higher albuminuria level or to end-stage renal disease, whereas 8.6% had a CVD event. The SD of serial A1C was 1.01 versus 0.75 (P
Notes
Cites: N Engl J Med. 2005 Dec 22;353(25):2643-5316371630
Cites: Scand J Clin Lab Invest. 2005;65(6):453-6216179278
Cites: Diabetes Care. 2006 Jul;29(7):1486-9016801566
Cites: Am Heart J. 2006 Jul;152(1):27-3816824829
Cites: Nat Clin Pract Endocrinol Metab. 2005 Dec;1(2):100-1016929378
Cites: Diabetologia. 2007 Nov;50(11):2280-817768606
Cites: Diabetologia. 2008 Jan;51(1):183-9017994218
Cites: Diabetes Care. 2008 Feb;31(2):230-217959867
Cites: Diabetes. 2008 May;57(5):1349-5418299315
Cites: Diabetes Care. 2008 Nov;31(11):2198-20218650371
Cites: Diabetes Care. 2009 Jan;32(1):187-9219092168
Cites: Diabetes Care. 2009 Sep;32(9):1689-9319502539
Cites: N Engl J Med. 1993 Sep 30;329(14):977-868366922
Cites: Br J Ophthalmol. 1998 Jul;82(7):725-309924360
Cites: Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):1014-910195930
Cites: Diabetologia. 1999 Sep;42(9):1113-910447524
Cites: Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E924-3011595647
Cites: Diabetes Care. 2000 Jan;23(1):45-5010857967
Cites: Diabetes Care. 2005 Apr;28(4):777-8215793172
Cites: Nature. 2001 Dec 13;414(6865):813-2011742414
Cites: J Clin Invest. 2002 Mar;109(6):805-1511901189
Cites: J Diabetes Complications. 2003 Mar-Apr;17(2):78-8112614973
Cites: Diabetes Care. 2003 May;26(5):1374-912716791
Cites: Diabetes. 2003 Nov;52(11):2795-80414578299
Cites: Diabetes Care. 2004 Feb;27(2):530-714747240
Cites: Am J Physiol Renal Physiol. 2004 Aug;287(2):F268-7315113747
Cites: Ann Intern Med. 2004 Sep 21;141(6):421-3115381515
Cites: Arch Intern Med. 2004 Sep 27;164(17):1917-2415451768
Cites: Lancet. 1982 Jan 16;1(8264):121-46119509
Cites: Br Med J (Clin Res Ed). 1986 Nov 8;293(6556):1195-93096429
Cites: N Engl J Med. 1993 Jul 29;329(5):304-98147960
Cites: Arch Intern Med. 1994 Nov 14;154(21):2473-97979844
Cites: BMJ. 1996 Sep 28;313(7060):779-848842069
Cites: Arch Ophthalmol. 1998 Jul;116(7):874-869682700
Cites: Diabetologia. 1998 Jul;41(7):784-909686919
Cites: Diabetes Care. 2005 Aug;28(8):2019-2416043748
Cites: JAMA. 2006 Apr 12;295(14):1681-716609090
PubMed ID
19651819 View in PubMed
Less detail

Abnormal glucose regulation and gender-specific risk of fatal coronary artery disease in the HUNT 1 study.

https://arctichealth.org/en/permalink/ahliterature127351
Source
Scand Cardiovasc J. 2012 Aug;46(4):219-25
Publication Type
Article
Date
Aug-2012
Author
Erik Madssen
Lars Vatten
Tom Ivar Nilsen
Kristian Midthjell
Rune Wiseth
Ane Cecilie Dale
Author Affiliation
Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Source
Scand Cardiovasc J. 2012 Aug;46(4):219-25
Date
Aug-2012
Language
English
Publication Type
Article
Keywords
Aged
Blood Glucose - metabolism
Confidence Intervals
Coronary Artery Disease - epidemiology - metabolism - mortality
Diabetes Mellitus - metabolism
Female
Health Status Indicators
Humans
Male
Middle Aged
Norway
Proportional Hazards Models
Prospective Studies
Registries
Risk Assessment - methods
Sex Factors
Abstract
To assess fatal coronary artery disease (CAD) by gender and glucose regulation status.
47,951 people were followed up according to fatal CAD identified in the National Cause of Death Registry. Gender-effects of fatal CAD in people with impaired glucose regulation (IGR), newly diagnosed diabetes (NDM) or known diabetes (KDM) compared with people with normal glucose regulation (NGR) were calculated using Cox regression.
Using NGR as reference, the hazard ratios (HR, 95% confidence intervals) associated with IGR was 1.2 (0.8-1.9) for women and 1.2 (0.9-1.6) for men. The corresponding HRs were 1.6 (1.2-2.2) and 1.4 (1.1.-1.9) for NDM, and 2.5 (2.1-2.8) and 1.8 (1.6-2.1) for KDM. The gender-difference in mortality varied by category (P(interaction) = 0.003). Using women as the reference, the HRs for men were 2.1 (2.0-2.3) for NGR, 1.8 (1.0-3.3) for IGR, 1.6 (1.0-2.5) for NDM, and 1.2 (1.0-1.5) for KDM.
Diabetes mellitus, but not IGR, was associated with fatal CAD in both genders. The known gender-difference in CAD mortality was attenuated in people with abnormal glucose regulation, evident already in people with IGR.
PubMed ID
22303857 View in PubMed
Less detail

Abnormal screening glucose challenge test in pregnancy and future risk of diabetes in young women.

https://arctichealth.org/en/permalink/ahliterature149375
Source
Diabet Med. 2009 May;26(5):474-7
Publication Type
Article
Date
May-2009
Author
R. Retnakaran
B R Shah
Author Affiliation
Department of Medicine, University of Toronto, Toronto, ON, Canada.
Source
Diabet Med. 2009 May;26(5):474-7
Date
May-2009
Language
English
Publication Type
Article
Keywords
Adult
Blood Glucose - metabolism
Cohort Studies
Diabetes Mellitus, Type 2 - epidemiology
Female
Glucose Intolerance - blood - epidemiology
Glucose Tolerance Test
Humans
Middle Aged
Ontario - epidemiology
Prediabetic State - epidemiology
Predictive value of tests
Pregnancy
Pregnancy Complications - blood - epidemiology
Risk factors
Abstract
Pregnant women commonly undergo screening for gestational diabetes mellitus (GDM) using a 50-g glucose challenge test (GCT), followed by a diagnostic oral glucose tolerance test (OGTT) in those women in whom the GCT is abnormal. Although it has long been recognized that GDM is associated with subsequent Type 2 diabetes, it has recently emerged that any degree of abnormal antepartum glucose homeostasis predicts an increased risk of postpartum glucose intolerance. Thus, in this context, we sought to determine whether women who have a pregnancy complicated by an abnormal GCT, but who do not have GDM, are at increased risk of subsequent diabetes, compared with their peers with an abnormal GCT.
A population-based, retrospective cohort study was conducted. Women referred for an antepartum OGTT indicative of an abnormal GCT (n = 15 381), but without GDM, were matched (for age, region, socioeconomic status, and year of delivery) with up to four other women without such referral (n = 61 237). The two cohorts were followed over a median 6.4 years for the development of diabetes.
The rate of incident diabetes was 5.04 cases per 1000 person-years in the cohort of women who underwent an antepartum OGTT, compared with 1.74 cases per 1000 person-years in women without an OGTT. The hazard ratio for subsequent diabetes in women with an antepartum OGTT was 2.56 (95% confidence interval 2.28, 2.87) (P
Notes
Comment In: Diabet Med. 2010 Jun;27(6):72820546300
PubMed ID
19646185 View in PubMed
Less detail

Abnormal skin in toe webs is a marker for abnormal glucose metabolism. A cross-sectional survey among 1,849 adults in Finland.

https://arctichealth.org/en/permalink/ahliterature299221
Source
Sci Rep. 2017 08 22; 7(1):9125
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
08-22-2017
Author
Suvi-Päivikki Sinikumpu
Juha Auvinen
Jari Jokelainen
Laura Huilaja
Katri Puukka
Aimo Ruokonen
Sirkka Keinänen-Kiukaanniemi
Kaisa Tasanen
Markku Timonen
Author Affiliation
PEDEGO Research Unit, University of Oulu, Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, P.O. Box 20, Oulu, 90029, Finland. suvi-paivikki.sinikumpu@oulu.fi.
Source
Sci Rep. 2017 08 22; 7(1):9125
Date
08-22-2017
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Adult
Biomarkers
Blood glucose
Cross-Sectional Studies
Female
Finland - epidemiology
Glucose - metabolism
Humans
Male
Middle Aged
Skin - pathology
Toes
Abstract
Diabetes is undiagnosed disease and easy screening tools for it are warranted. Because foot complications are usual in diabetes, we aimed to test hypothesis that skin abnormalities are found already from patients who are not aware of having diabetes, by studying the possible association between unhealthy toe web skin and abnormal glucose metabolism. 1,849 cases without previously diagnosed diabetes participated to the 46-year follow-up study of the Northern Finland Birth Cohort. A skin investigation was performed for all, and abnormal skin findings in toe web spaces were taken as explanatory variables. Abnormal glucose tolerance was the main outcome and it was tested with an oral glucose tolerance test (OGTT), glycosylated haemoglobin fraction (HbA1c) Values are numbers (percentages) of sub and fasting blood glucose. The participants who had any abnormal skin findings in toe webs were associated with 2.5-fold (OR 2.5, 95% CI 1.3-4.9) and 6-fold (OR 6.2, 1.4-27.6) increased risk of having previously undiagnosed diabetes detected by a 2-hour OGTT and HbA1c, respectively. The predictive power of toe web findings was comparable with FINDRISC score. Abnormal skin findings in the toe webs show increased risk of occult diabetes, and may, thus serve as an additional sign of undiagnosed diabetes.
PubMed ID
28831117 View in PubMed
Less detail

Absence of association between genetic variation of the beta 3-adrenergic receptor and metabolic phenotypes in Oji-Cree.

https://arctichealth.org/en/permalink/ahliterature205667
Source
Diabetes Care. 1998 May;21(5):851-4
Publication Type
Article
Date
May-1998
Author
R A Hegele
S B Harris
A J Hanley
H. Azouz
P W Connelly
B. Zinman
Author Affiliation
Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, London, Ontario, Canada. robert.hegele@rri.on.ca
Source
Diabetes Care. 1998 May;21(5):851-4
Date
May-1998
Language
English
Publication Type
Article
Keywords
Adipose Tissue - metabolism
Adult
Alleles
American Native Continental Ancestry Group - genetics
Analysis of Variance
Blood Glucose - metabolism
Body constitution
Body mass index
Diabetes Mellitus, Type 2 - blood - epidemiology - genetics
Female
Gene Frequency
Genetic Variation
Genotype
Humans
Insulin - blood
Male
Middle Aged
Ontario - epidemiology
Phenotype
Receptors, Adrenergic, beta - genetics
Abstract
To assess the association between the common missense variant, Y64R, in the gene encoding the beta 3-adrenergic receptor, ADRB3, and intermediate phenotypes related to obesity and NIDDM in Canadian Oji-Cree.
We determined genotypes of the ADRB3 Y64R polymorphism in 508 clinically and biochemically well-characterized adult Oji-Cree, of whom 115 had NIDDM. We tested for associations with multivariate analysis of variance.
We found the ADRB3 R64 allele frequency to be 0.40 in this population, which is the highest yet observed in a human population. Furthermore, 15% of subjects were R64/R64 homozygotes, compared with a virtual absence of homozygotes in European study samples. However, we found no statistically significant associations of the ADRB3 Y64R genotype either with the presence of NIDDM, with indexes of obesity, or with intermediate quantitative biochemical traits related to NIDDM.
Despite the very high frequency of the ADRB3 R64 allele in this sample of aboriginal people, it was not associated with any metabolic phenotype. This suggests that the ADRB3 R64 allele is probably not a major determinant of obesity or NIDDM in these aboriginal Canadians.
PubMed ID
9589254 View in PubMed
Less detail

925 records – page 1 of 93.